Jefferies trims CSL's PT as growth in key markets falls short of 'stellar'

Csl

12/04/2026 20:22

** Brokerage Jefferies cuts Australian biopharmaceutical firm CSL's CSL.AX target price to A$212 from A$235, with a "buy" rating

** Brokerage says growth in CSL's key markets, immunoglobulin sales in the United States and albumin demand in China are not "stellar"

** Says demand concerns cast doubt on CSL's goal of strong second half of 2026

** Jefferies says immunoglobulin & albumin markets remain underpenetrated and should grow over the medium term

** 10 of 16 brokerages rate the stock "buy" or higher, while 6 rate it "hold"; their median PT is A$200 - LSEG data

** As of last close, stock had fallen 0.74%

 (Reporting by Sruthi Narasimha Chari in Bengaluru; Editing by Edmund Klamann)

 ((Sruthinarasimha.chari@thomsonreuters.com))